Lung microbiome and disease progression in idiopathic pulmonary fibrosis: An analysis of the COMET study

The Lancet Respiratory Medicine

Volumn 2, Issue 7, 2014, Pages 548-556

  Han, MeiLan K ^a   Zhou, Yueren ^a   Murray, Susan ^a   Tayob, Nabihah ^a   Noth, Imre ^b   Lama, Vibha N ^a   Moore, Bethany B ^a   White, Eric S ^a   Flaherty, Kevin R ^a   Huffnagle, Gary B ^a   Martinez, Fernando J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; BACTERIAL DNA;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEATH; DISEASE COURSE; DISEASE EXACERBATION; DNA ISOLATION; DNA SEQUENCE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; GENETIC VARIABILITY; HUMAN; LUNG DIFFUSION CAPACITY; LUNG LAVAGE; LUNG MICROBIOME; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROBIOME; NONHUMAN; POPULATION ABUNDANCE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYROSEQUENCING; STAPHYLOCOCCUS; STREPTOCOCCUS; SURVIVAL RATE; TAXONOMY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; ISOLATION AND PURIFICATION; LUNG; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY; VITAL CAPACITY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MALE; MICROBIOTA; MIDDLE AGED; SEQUENCE ANALYSIS, DNA; STAPHYLOCOCCUS; STREPTOCOCCUS; VITAL CAPACITY;

EID: 84903993583     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70069-4     Document Type: Article

References (38)

1. Noth I, Zhang Y, Swhu-Fan M, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013, 1:309-317.
2. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013, 45:1409.
3. O'Dwyer DN, Armstrong ME, Trujillo G, et al. The toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2013, 188:1442-1450.
4. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013, 309:2232-2239.
5. Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013, 5:205ra136.
6. Gilani SR, Vuga LJ, Lindell KO, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One 2010, 5:e8959.
7. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008, 5:e93.
8. Molyneaux PL, Maher TM The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev 2013, 22:376-381.
9. Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 2013, 68:155-162.
10. Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive lung disease. Thorax 2012, 67:456-463.
11. Naik PK, Bozyk PD, Bentley JK, et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012, 303:L1046-L1056.
12. Mason KL, Erb Downward JR, Mason KD, et al. Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad-spectrum antibiotic therapy. Infect Immun 2012, 80:3371-3380.
13. Daigle D, Simen BB, Pochart P High-throughput sequencing of PCR products tagged with universal primers using 454 life sciences systems. Curr Protoc Mol Biol 2011, chapter 7: unit 7 5.
14. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
15. Flaherty KR, Andrei AC, King TE, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?. Am J Respir Crit Care Med 2007, 175:1054-1060.
16. Flaherty KR, King TE, Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?. Am J Respir Crit Care Med 2004, 170:904-910.
17. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007, 176:636-643.
18. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 2009, 75:7537-7541.
19. Hastie T, Tibshirani R, Friedman J The elements of statistical learning 2009, Springer-Verlag.
20. Tian L, Tibshirani R Adaptive index models for marker-based risk stratification. Biostatistics 2011, 12:68-86.
21. Han MK, Murray S, Fell CD, et al. Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J 2008, 31:1183-1188.
22. Evaluation of 16S rDNA-based community profiling for human microbiome research. PLoS One 2012, 7:e39315.
23. Maher TM, Wells AU, Laurent GJ Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. Eur Respir J 2007, 30:835-839.
24. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012, 366:1968-1977. Idiopathic Pulmonary Fibrosis Clinical Research Network.
25. McMillan TR, Moore BB, Weinberg JB, et al. Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus. Am J Respir Crit Care Med 2008, 177:771-780.
26. Wootton SC, Kim DS, Kondoh Y, et al. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183:1698-1702.
27. Konishi K, Gibson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009, 180:167-175.
28. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One 2011, 6:e16384.
29. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One 2010, 5:e8578.
30. Huang YJ, Kim E, Cox MJ, et al. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. OMICS 2010, 14:9-59.
31. Garzoni C, Brugger SD, Qi W, et al. Microbial communities in the respiratory tract of patients with interstitial lung disease. Thorax 2013, 68:1150-1156.
32. Richter AG, Stockley RA, Harper L, Thickett DR Pulmonary infection in Wegener granulomatosis and idiopathic pulmonary fibrosis. Thorax 2009, 64:692-697.
33. Varney VA, Parnell HM, Salisbury DT, Ratnatheepan S, Tayar RB A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease. Pulm Pharmacol Ther 2008, 21:178-187.
34. Trujillo G, Meneghin A, Flaherty KR, et al. TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med 2010, 2:57ra82.
35. Parker D, Prince A Staphylococcus aureus induces type I IFN signaling in dendritic cells via TLR9. J Immunol 2012, 189:4040-4046.
36. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006, 27:136-142.
37. Morris A, Beck JM, Schloss PD, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med 2013, 187:1067-1075.
38. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012, 185:1044-1048.